Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
151.57
-0.01 (-0.01%)
Nov 28, 2025, 11:04 AM EST - Market open
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $794.90M in the quarter ending September 30, 2025, with 27.78% growth. This brings the company's revenue in the last twelve months to $2.68B, up 19.61% year-over-year. In the year 2024, Neurocrine Biosciences had annual revenue of $2.36B with 24.81% growth.
Revenue (ttm)
$2.68B
Revenue Growth
+19.61%
P/S Ratio
5.62
Revenue / Employee
$1,490,389
Employees
1,800
Market Cap
15.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.36B | 468.20M | 24.81% |
| Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
| Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
| Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
| Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NBIX News
- 8 days ago - Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules - PRNewsWire
- 8 days ago - Nvidia Earnings Pivot? 5 Best Stocks For Sector Rotation Out Of Tech - Seeking Alpha
- 9 days ago - A Strong Crenessity Launch And Muscarinic Pipeline Can Propel Neurocrine Biosciences Further - Seeking Alpha
- 10 days ago - Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 16 days ago - Neurocrine Biosciences to Present at Upcoming Investor Conferences - PRNewsWire
- 16 days ago - Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile - Benzinga
- 17 days ago - Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder - PRNewsWire
- 25 days ago - Biotech is back. Here's why these rallying stocks belong in your portfolio now. - Market Watch